1,380 Shares in United Therapeutics Co. (NASDAQ:UTHR) Purchased by Everence Capital Management Inc.

Everence Capital Management Inc. purchased a new position in United Therapeutics Co. (NASDAQ:UTHR) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 1,380 shares of the biotechnology company’s stock, valued at approximately $487,000.

Several other institutional investors also recently bought and sold shares of the business. Tri Locum Partners LP purchased a new stake in United Therapeutics during the second quarter worth $15,959,000. Franklin Resources Inc. boosted its position in United Therapeutics by 97.7% during the third quarter. Franklin Resources Inc. now owns 250,719 shares of the biotechnology company’s stock valued at $89,532,000 after purchasing an additional 123,929 shares in the last quarter. Bridgewater Associates LP grew its stake in United Therapeutics by 384.3% in the third quarter. Bridgewater Associates LP now owns 61,755 shares of the biotechnology company’s stock valued at $22,130,000 after purchasing an additional 49,003 shares during the last quarter. Glenmede Trust Co. NA grew its position in shares of United Therapeutics by 6.4% in the 3rd quarter. Glenmede Trust Co. NA now owns 68,605 shares of the biotechnology company’s stock worth $24,585,000 after buying an additional 4,145 shares during the last quarter. Finally, Renaissance Technologies LLC raised its stake in shares of United Therapeutics by 1.1% during the 2nd quarter. Renaissance Technologies LLC now owns 2,174,692 shares of the biotechnology company’s stock worth $692,748,000 after acquiring an additional 22,978 shares in the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the stock. LADENBURG THALM/SH SH raised their target price on shares of United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. TD Cowen boosted their target price on United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. Argus increased their price target on United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. The Goldman Sachs Group boosted their price target on United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a research note on Friday, November 1st. Finally, StockNews.com raised shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Monday, December 30th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $370.86.

Insider Activity at United Therapeutics

In related news, Director Christopher Causey sold 510 shares of United Therapeutics stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $376.63, for a total value of $192,081.30. Following the completion of the transaction, the director now owns 3,675 shares in the company, valued at $1,384,115.25. The trade was a 12.19 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Judy D. Olian sold 1,750 shares of the company’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $412.48, for a total value of $721,840.00. Following the completion of the transaction, the director now directly owns 5,655 shares of the company’s stock, valued at $2,332,574.40. The trade was a 23.63 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 142,422 shares of company stock worth $53,498,732 in the last three months. Company insiders own 11.90% of the company’s stock.

United Therapeutics Stock Performance

Shares of UTHR opened at $356.33 on Monday. The business’s 50-day moving average is $370.42 and its two-hundred day moving average is $351.01. The company has a market capitalization of $15.91 billion, a P/E ratio of 15.65, a P/E/G ratio of 1.05 and a beta of 0.57. United Therapeutics Co. has a fifty-two week low of $208.62 and a fifty-two week high of $417.82.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, topping the consensus estimate of $6.16 by $0.23. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm had revenue of $748.90 million for the quarter, compared to analyst estimates of $722.62 million. During the same period last year, the company earned $5.38 earnings per share. United Therapeutics’s revenue for the quarter was up 22.9% compared to the same quarter last year. Analysts forecast that United Therapeutics Co. will post 25.22 EPS for the current year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.